Survodutide

Dual GLP-1/glucagon agonist in development

4.5
2 reseñas

Rating Breakdown

Weight Loss Efficacy
4.5
Appetite Suppression
4.0
Metabolic Improvement
4.5
Body Composition
4.5
Glycemic Control
3.0
Safety & Side Effects
3.5
Cardiovascular Benefit
3.0
Dosing Convenience
4.0

Resumen

Survodutide is a dual GLP-1 and glucagon receptor agonist that combines appetite suppression with direct fat oxidation.

Key Information

Identity
Also Known As BI 456906
Sequence Dual GLP-1/glucagon agonist peptide
CAS Number 2223773-18-8
Molecular Formula C164H262N40O49
Properties
Half-Life Several days
Administration subcutaneous injection
Dosage Range 0.6-4.8 mg weekly
Price Range $3.0–$20.0/mg
Handling & Storage
Storage Refrigerated 2-8C
Reconstitution Reconstitute with bacteriostatic water
Regulatory Status
US Status Investigational (Phase 3)
Legal Status Investigational — Phase 3 development.
Research Papers 1 indexed

Mecanismo

Dual agonism of GLP-1 (appetite) and glucagon (fat oxidation, thermogenesis) receptors.

Benefits

  • Up to 19% weight loss
  • Dual GLP-1/glucagon mechanism
  • Fat oxidation + appetite suppression

Side Effects

  • Nausea
  • Diarrhea
  • Vomiting

Contraindications

  • Not studied in pregnancy

Evidence Summary

Phase 2 showed up to 19% weight loss at 46 weeks. Phase 3 ongoing.

Research

Phase 2 showed up to 19% weight loss at 46 weeks.

Ver Investigación

Safety

GI side effects similar to GLP-1 class.

Legal Status

Investigational — Phase 3 development.

Investigación

1 artículos de investigación indexados

Ver Investigación

Write a Review

Rating Breakdown

Eficacia
4.5
Seguridad
3.5
Valor
4.0
Overall
4.5

Based on 2 reseñas.

Reseñas

19% weight loss in trials is impressive 2026-08-03
Olivia N.

Participated in a trial. Lost 17% of body weight in 6 months. The glucagon component really helps with fat burning. Less nausea than pure GLP-1 agonists. Excited for approval.

Eficacia: 5/5 Seguridad: 4/5 Valor: 4/5
Promising dual agonist 2026-07-24
Tom Z.

Been on survodutide for 3 months, down 16 lbs. The GLP-1/glucagon dual mechanism gives good fat oxidation. Appetite suppression is decent but not as strong as tirzepatide. Looking forward to more data.

Eficacia: 4/5 Seguridad: 3/5 Valor: 4/5